Searched for
INDIAN PHARMACEUTICAL GIANT
Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...- 'Not a great environment for Indian market': Harsha Upadhyaya on Iran-US tensions, IT outlook, pharma bet, and where to be cautiousGlobal challenges are impacting Indian stocks. West Asian tensions and rising US inflation create headwinds. Tech sector shifts also affect...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...
- 'India more diversified:' Sebi chief Tuhin Kanta Pandey comments on Taiwan's market ascentSEBI chief Tuhin Kanta Pandey emphasized India remains a diversified market despite Taiwan overtaking its market value. Driven by TSMC and ...
- Parle Melody: The ₹1 soft power twist Modi served to Meloni and the worldPrime Minister Modi's gift of a Parle Melody toffee to Italy's Giorgia Meloni symbolised India's evolving soft power. Beyond traditional ex...
- Sensex surges over 800 points to cross 75,400; Nifty above 23,650 despite weak rupeeIn a recent turn of fortunes, Indian stock markets experienced a notable rise for the second consecutive day. On Thursday, both the Sensex ...
- The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...
- Sun's strong gravity helps India Inc's pullSun Pharma has expanded its horizons by acquiring Organon, a notable New Jersey pharmaceutical firm. This strategic acquisition fortifies S...
- Sun Pharma deal structurally strong, debt the only overhang: Amit KhuranaMarket expert Amit Khurana offers insights on key corporate and regulatory developments. Sun Pharma's acquisition is seen as strategically ...
- “No Bull, no bear—it’s a kangaroo market," says Nilesh Shah amid global uncertaintyIndian markets show a recovery but face a "kangaroo market" due to global risks like West Asian tensions and oil price volatility. Investor...
- Most hated stocks: FIIs dumping these 146 companies without a break for 4 straight quarters. Do you own any?Foreign institutional investors have been consistently selling shares in 146 Indian companies for four consecutive quarters. This selling s...
- Indian market faces AI narrative problem; it'll be smallcaps over largecaps for next 5 years: Manish GunwaniIndian stock market valuations are attractive. However, global investor focus on Artificial Intelligence is diverting capital away from eme...
- Indian pharma sector faces supply risk amid West Asia conflict despite duty waiverIndia's pharmaceutical industry faces ongoing concerns about securing essential petrochemical supplies due to the West Asia conflict. While...
- Amgen to invest $200 million in India site, CEO saysAmgen will invest $200 million in its new technology centre in Hyderabad, India, this year, with plans for further investments. The centre,...
- Sun Pharma enters settlement in antitrust litigation in US"Sun Pharmaceutical Industries Ltd, and one of its wholly-owned subsidiaries have entered into settlements with certain plaintiffs in re Mo...
- China's Shanghai Fosun to acquire 86% stake in Gland Pharma for $1.4 billionShanghai Fosun will acquire the shares held by Gland Pharma founders Ravi Penmetsa and his family and PE giant KKR.
- Chinese aid norms curb exports of Indian drugs to markets in Africa, Asia & eastern EuropeIndia exported $15.2 billion medicines in 2014-15 and around 15% of these medicines were sold in economies that are availing concessional l...
- Global drug majors bid for India's Paras: reportBritish giant GlaxoSmithKline, France's Sanofi-Aventis, Swiss multinational Novartis, and US-based Johnson and Johnson have all made bids f...
- Malaysia offers good incentives for Indian biotech companiesMalaysia is keen to work with Indian companies venturing into biotechnology as it has offered attractive incentives and infrastructure to t...
Load More
